Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adalimumab - AbbVie/MedImmune

Drug Profile

Adalimumab - AbbVie/MedImmune

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 24 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hidradenitis suppurativa; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Phase III Pyoderma
  • Discontinued Interstitial cystitis

Most Recent Events

  • 24 Dec 2018 Tel-Aviv Sourasky Medical Center completes a phase III trial for Crohn's Disease in Israel, before December 2018 (NCT01629628)
  • 30 Nov 2018 AbbVie enters into a non-exclusive patent license agreement with Pfizer over adalimumab biosimilar
  • 06 Nov 2018 AbbVie enters into a non-exclusive patent license agreement with Momenta over adalimumab biosimilar
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top